{"id":3226,"date":"2013-05-08T06:30:00","date_gmt":"2013-05-08T06:30:00","guid":{"rendered":"https:\/\/www.xvivogroup.com\/us\/mfn_news\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/"},"modified":"2013-05-08T06:30:00","modified_gmt":"2013-05-08T06:30:00","slug":"report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8","status":"publish","type":"mfn_news","link":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/","title":{"rendered":"Report from Annual General Meeting of XVIVO Perfusion AB (publ)"},"content":{"rendered":"<\/p>\n

At XVIVO Perfusion\u2019s Annual General Meeting yesterday, May 7, the following, amongst other things, was decided:<\/span><\/p>\n<\/p>\n

\u2022 No dividend will be paid for the financial year 2012.<\/span><\/p>\n

\u2022 Re-election of Board members Semmy R\u00fclf, Erik von Schenck, Magnus Nilsson and Fredrik Mattsson and new election of Folke Nilsson and G\u00f6sta Johannesson, in accordance with Bure\u2019s proposal. Fredrik Mattsson was re-elected Chairman of the Board.<\/span><\/p>\n

\u2022 Remuneration to the members of the Board shall be SEK 470,000 in total, of which SEK 150,000 is allocated to the Chairman of the Board and SEK 80,000 to each Board member who are not an employee of the company.<\/span><\/p>\n

\u2022 Election of KPMG as auditor, with authorized public accountant Jan Malm as the principal auditor.<\/span><\/p>\n

\u2022 Establishment of nomination committee for the next annual general meeting, in accordance with Bure's proposal.<\/span><\/p>\n

\u2022 Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a maximum of 1,950,000 shares in total, corresponding to just below 10 percent of the company\u2019s share capital.<\/span><\/p>\n

\u2022 The proposed principles for remuneration and other conditions of employment for the senior management were approved.<\/span><\/p>\n

\u2022 The proposed issuance of a total of 195,000 warrants with the right to subscribe for new shares was approved. The warrants shall be offered to employees in the XVIVO Perfusion Group. Upon full exercise of the warrants, the share capital increase is SEK 2,500 corresponding to a dilution of about 1 percent of the total number of shares and votes.<\/span><\/p>\n

May 8, 2013
<\/span>Gothenburg<\/span>
<\/span>XVIVO Perfusion AB (publ)
<\/span>The Board<\/span><\/p>\n<\/p>\n

\n

Queries should be addressed to:<\/span><\/p>\n

Fredrik Mattsson, Chairman of the Board, phone +46 8-614 00 20<\/span>
Christoffer Rosenblad, CFO, phone +46 31-788 21 59<\/span><\/p>\n<\/p>\n

Xvivo Perfusion is required to publish the information in this press release in accordance with the Swedish Securities Market Act and\/or the Financial Instruments Trading Act. The information was submitted for publication on\u00a0May 8, 2013\u00a0at 8:30 a.m.<\/span><\/p>\n

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.<\/span><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

At XVIVO Perfusion\u2019s Annual General Meeting yesterday, May 7, the following, amongst other things, was decided: \u2022 No dividend will…<\/p>\n","protected":false},"template":"","class_list":["post-3226","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-lang-en","mfn-news-tag-mfn-regulatory","mfn-news-tag-mfn-regulatory-vpml","mfn-news-tag-mfn-ci","mfn-news-tag-mfn-ci-gm","mfn-news-tag-mfn-ci-gm-info","mfn-news-tag-mfn","mfn-news-tag-mfn-type-ir"],"acf":[],"yoast_head":"\nReport from Annual General Meeting of XVIVO Perfusion AB (publ) - XVIVO<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Report from Annual General Meeting of XVIVO Perfusion AB (publ) - XVIVO\" \/>\n<meta property=\"og:description\" content=\"At XVIVO Perfusion\u2019s Annual General Meeting yesterday, May 7, the following, amongst other things, was decided: \u2022 No dividend will...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/\" \/>\n<meta property=\"og:site_name\" content=\"United States\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\\\/\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\\\/\",\"name\":\"Report from Annual General Meeting of XVIVO Perfusion AB (publ) - XVIVO\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\"},\"datePublished\":\"2013-05-08T06:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/pressreleases\\\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Report from Annual General Meeting of XVIVO Perfusion AB (publ)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/#website\",\"url\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/\",\"name\":\"United States\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.xvivogroup.com\\\/us\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Report from Annual General Meeting of XVIVO Perfusion AB (publ) - XVIVO","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/","og_locale":"en_US","og_type":"article","og_title":"Report from Annual General Meeting of XVIVO Perfusion AB (publ) - XVIVO","og_description":"At XVIVO Perfusion\u2019s Annual General Meeting yesterday, May 7, the following, amongst other things, was decided: \u2022 No dividend will...","og_url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/","og_site_name":"United States","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/","url":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/","name":"Report from Annual General Meeting of XVIVO Perfusion AB (publ) - XVIVO","isPartOf":{"@id":"https:\/\/www.xvivogroup.com\/us\/#website"},"datePublished":"2013-05-08T06:30:00+00:00","breadcrumb":{"@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.xvivogroup.com\/us\/pressreleases\/report-from-annual-general-meeting-of-xvivo-perfusion-ab-publ-8\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.xvivogroup.com\/us\/"},{"@type":"ListItem","position":2,"name":"Report from Annual General Meeting of XVIVO Perfusion AB (publ)"}]},{"@type":"WebSite","@id":"https:\/\/www.xvivogroup.com\/us\/#website","url":"https:\/\/www.xvivogroup.com\/us\/","name":"United States","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.xvivogroup.com\/us\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news\/3226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/www.xvivogroup.com\/us\/wp-json\/wp\/v2\/media?parent=3226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}